This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Niacinamide (Nicotinamide)
Niacinamide (nicotinamide, NAM) is the amide form of vitamin B3 — a cheap, exceptionally well-tolerated NAD+ precursor that bypasses niacin's GPR109A-mediated flush.
Aliases (4)
Overview
What is Niacinamide (Nicotinamide)?
Niacinamide (nicotinamide) is the amide form of vitamin B3, a precursor for the coenzymes NAD+ and NADP+. It is used as a dietary supplement, in dermatology for skin barrier and pigmentation support, and at high doses as a chemopreventive against non-melanoma skin cancer.
Key Benefits
Improves skin barrier function, reduces hyperpigmentation, and lowers risk of non-melanoma skin cancers in high-risk patients (ONTRAC trial, 500 mg BID). Supports NAD+ precursor pool without the flushing of nicotinic acid; used in some early Alzheimer's and inflammatory skin condition protocols.
Mechanism of Action
Phosphoribosylated to nicotinamide mononucleotide (NMN) and adenylated to NAD+, raising cellular NAD+ pools. Inhibits PARP and sirtuin enzymes at high concentrations, preserving cellular ATP after DNA damage and modulating UV-induced immunosuppression in skin.
Pharmacokinetics
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
Same NAD+ pathway from different entry points. Stacking is not necessary — most NMN/NR ends up as NAM anyway in vivo. Some users layer all three at lower dos…
CD38 inhibition (apigenin) + NAD+ supply (niacinamide) is the Sinclair-lab template for sustaining NAD+ levels — slowing breakdown while supplying precursor.…
Theoretically synergistic — SIRT1 activators paired with the SIRT1 substrate (NAD+). Trans-resveratrol has modest human bioavailability; pterostilbene is the…
Counterbalance methyl-group demand at chronic high doses. Mandatory pair if going >500 mg/day chronic, especially in MTHFR variants. Cheap insurance.
Topical niacinamide reduces retinoid-induced irritation while complementing the anti-aging mechanism. Standard dermatology pairing (the Discord anecdote in t…
Compound mitochondrial cofactor support. Mechanistically coherent for athletic recovery and post-injury healing.
Redundant pathway saturation + additive 4PY metabolite load.
Both interact with B6/B3 metabolism; clinically minor for niacinamide vs niacin but worth flagging.
Xu 2025 JAAD review flags 2E1-metabolized co-medications as risk-amplifiers — relevant only for users on isoniazid, disulfiram, or chronic high alcohol.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety 6
Side Effects
- 1None at standard supplemental doses (≤500 mg). Niacinamide has one of the cleanest acute safety profiles in the entire supplement category.
- 2At 1-2 g/day: Mild GI discomfort, occasional nausea, mild warmth in some users.
- 3GI symptoms at >500 mg: mild nausea, occasional cramping, soft stool
- 4Mild flushing or warmth in sensitive users (not the niacin flush — uncertain mechanism, possibly histamine-related)
- 5Headache at high doses, especially first week of dose escalation
- 6Sleep changes — usually deeper at 500-1000 mg pre-bed, occasionally fragmented at 1500 mg+
When to Stop
- Hepatotoxicity at >3 g/day chronic. Case literature documents elevated ALT/AST, occasional cholestatic injury, and rare frank hepatitis at chronic high doses. Reversible on discontinuation. Cumulative dose matters more than peak exposure.
- Insulin resistance signal at >1.5 g/day chronic — clinically modest but real. Multiple studies report 5-15% reduction in insulin sensitivity in healthy adults given chronic 1500 mg+ NAM. Mechanism: hepatic NAD+ flux changes alter glucose handling. Most studies show normalization within 4-8 weeks of stopping.
- Cardiovascular event signal (post-Hazen 2024): 2PY/4PY metabolites associated with ~doubled 3-year MACE risk in observational cohorts. Mechanism: VCAM-1 induction + endothelial leukocyte adhesion. Strongest novel safety signal in 10 years. Most relevant in chronic dosing >500 mg/day in patients with established or borderline cardiovascular risk. For a 20yo with no CV risk factors the absolute risk is small but the signal merits dose discipline.
- Methyl-donor depletion: Chronic high-dose niacinamide is methylated to N-methyl-nicotinamide for excretion, consuming SAMe (S-adenosylmethionine) and methyl-pool capacity. Theoretical homocysteine elevation if folate/B12 status is suboptimal; documented at 1500 mg/day chronic.
- Thrombocytopenia, lymphopenia, anemia — documented at chronic high doses in case reports; reversible.
- Bladder cancer signal — observational correlation between elevated NAM metabolites and bladder cancer reported in Xu 2025 JAAD review. Confounding (smoking, age) not fully controlled in source studies; warrants watching but not actionable in healthy users.
- Pregnancy: Generally regarded as safer than niacin (no flush, no GPR109A activation). Topical nicotinamide considered low-risk. Oral doses ≤500 mg/day used in some chemoprevention trials including pregnant subgroups without harm signal. No human teratogenicity data at megadoses.
- Breastfeeding: NAM is present in breast milk normally. Supplemental low-dose use generally fine; high-dose use under-studied.
- First 2 weeks at >500 mg: GI tolerance, headache adjustment
- First 3 months at >1 g/day: ALT/AST + glucose check (especially in users with any liver or metabolic comorbidity)
- Chronic >6 months at >500 mg/day: Annual lipid panel + CRP + (if available) plasma 2PY/4PY screening, given the Hazen 2024 signal
- Any concomitant hepatotoxic drug or alcohol use: Lower threshold for monitoring
References
Chen et al. 2015 — ONTRAC trial: nicotinamide for skin-cancer chemoprevention (NEJM)
landmark phase 3 RCT; 23% reduction in new NMSC at 500 mg BID × 12 months in immunocompetent adults with prior keratinocyte cancer.
View StudyAllen et al. 2023 — ONTRANS: nicotinamide for skin cancer in transplant recipients (NEJM)
phase 3 RCT, n=158 transplant recipients; no significant benefit on keratinocyte cancers. Narrows chemoprevention claim.
View StudyFerrell/Hazen et al. 2024 — Terminal niacin metabolite 4PY promotes vascular inflammation and CV disease risk (Nature Medicine)
discovery + 2 validation cohorts, n=4,300+; 2PY/4PY associated with ~doubled 3-year MACE; VCAM-1 + leukocyte-adhesion mechanism. Most important new safety signal.
View StudyBreglio et al. 2025 — Nicotinamide for skin cancer chemoprevention (JAMA Dermatology)
retrospective VA cohort, ~34,000 patients 1999-2024; 14% overall NMSC reduction, 54% if started after first NMSC.
View StudyHwang & Song 2020 — Possible adverse effects of high-dose nicotinamide: mechanisms and safety assessment (Biomolecules)
foundational safety review anticipating the 2024 metabolite/CV signal.
View StudyShoukfeh et al. 2025 — Cardiovascular impacts of oral nicotinamide narrative review (J Drugs Dermatol)
explicit clinical guidance to limit chronic NAM to ≤500 mg/day post-Hazen 2024.
View StudyXu et al. 2025 — Safety of nicotinamide for skin cancer prevention (JAAD Reviews)
comprehensive 2025 safety review; metabolism, toxic dosages, populations at risk.
View StudyTrammell et al. 2016 — Nicotinamide riboside vs nicotinamide pharmacokinetics (Nat Commun)
established NAM ~ NR equivalence for liver/muscle NAD+.
View StudyLiu et al. 2018 — Quantitative analysis of NAD synthesis pathway (Cell Metab)
mouse pathway analysis + lifespan extension on high-fat diet.
View StudyWu et al. 2025 — NR in older adults with subjective cognitive decline / MCI (Alz Dement TRCI)
raised NAD+, did NOT improve cognition; tempers NAD+-precursor cognitive claims.
View StudyBrakedal/Tzoulis 2022 — NADPARK: NR phase I in Parkinson's (Cell Metab)
demonstrated cerebral NAD+ elevation with oral NR.
View StudyPhelps et al. 2017 — Phase 2 nicotinamide for mild-to-moderate Alzheimer's (NCT00580931)
1500 mg/day × 24 wk pilot; modest signal, did not progress to Phase 3.
View StudyBogan & Brenner 2008 — NAD precursor vitamins (Annu Rev Nutr review)
classic mechanistic synthesis of B3 vitamers and NAD+ biosynthesis.
View StudyNiacin — NIH ODS Health Professional Fact Sheet
official RDA, UL, dietary sources, current safety guidance.
View StudyThe adverse effects of oral niacin/nicotinamide — overview of reviews
2025 umbrella review consolidating safety signals across both forms.
View StudyLatest research
- reviewShoukfeh et al. — Cardiovascular impacts of oral nicotinamide (narrative review)J Drugs Dermatol 2025 review explicitly cautions against high-dose chronic NAM following 2024 4PY/MACE data; recommends staying ≤500 mg in chronic use absent specific indication.
- rctWu et al. — Nicotinamide riboside in subjective cognitive decline + MCIAlz Dement TRCI 2025 — 12 wk oral NR in older adults with SCD/MCI; raised blood NAD+ but did not improve cognition. Caveat to high-dose NAM/NR longevity claims at this duration.
- reviewXu et al. — Safety of nicotinamide for skin cancer prevention (JAAD Reviews)2025 JAAD review of metabolism and toxic dosages; up to 1 g/day generally well-tolerated but flags renal/hepatic-impaired populations + CYP450 2E1 drug interactions + correlated metabolites linked to bladder cancer + metabolic syndrome.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.